Literature DB >> 21827968

Adjuvant radiotherapy and health-related quality of life of patients at intermediate risk of recurrence following primary surgery for oral squamous cell carcinoma.

F Bekiroglu1, N Ghazali, R Laycock, C Katre, D Lowe, S N Rogers.   

Abstract

Controversy surrounds who should receive adjuvant radiotherapy in patients with intermediate risk of recurrence of oral squamous cell carcinoma following primary surgery. The aim of this study was to compare health-related quality of life (HRQOL) outcomes of those who received adjuvant radiotherapy to those who did not in patients at intermediate-risk of recurrence. A total of 765 oral cancer patients were treated at the Regional Maxillofacial Unit, Liverpool from 1995 to 2007. After excluding 124 patients (87 primary radiotherapy, 23 died within 90 days, 14 had insufficient information for determining risk group status), 169 were low-risk, 271 intermediate-risk and 201 were high-risk. In the intermediate-risk group, 33% had adjuvant radiotherapy. Allowing for attrition, more than 70% had University of Washington quality of life data (UW-QOL). Cumulative survival was similar in those with and without adjuvant radiotherapy in a subset of patients at intermediate risk. There was little difference in overall HRQOL scores and in the socio-emotional subscale scores of the UW-QOL. However, there was a significant difference in physical subscale scores and the issue most affected was saliva. These findings support better stratification of risk in the intermediate group, and the plausibility of withholding radiotherapy without compromising survival. This can have dramatic positive benefits on patient physical outcomes, in particular saliva. Where adjuvant radiotherapy is necessary, it is appropriate to minimise adverse effects through measures such as intensity-modulated radiation therapy.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21827968     DOI: 10.1016/j.oraloncology.2011.07.003

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  5 in total

1.  Variation in treatment and outcome in the early stage oral cavity squamous cell carcinoma.

Authors:  Darragh S Gogarty; Paul Lennon; Sandra Deady; J Barry O'Sullivan; Orla McArdle; Mary Leader; Patrick Sheahan; James Paul O'Neill
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-08-23       Impact factor: 2.503

2.  Characteristics and referral of head and neck cancer patients who report chewing and dental issues on the Patient Concerns Inventory.

Authors:  R Mahmood; C Butterworth; D Lowe; S N Rogers
Journal:  Br Dent J       Date:  2014-06-13       Impact factor: 1.626

3.  Oral health-related quality of life and malnutrition in patients treated for oral cancer.

Authors:  Rocío Barrios; Georgios Tsakos; Blas García-Medina; Ildefonso Martínez-Lara; Manuel Bravo
Journal:  Support Care Cancer       Date:  2014-05-22       Impact factor: 3.603

Review 4.  Levels of scientific evidence of the quality of life in patients treated for oral cancer.

Authors:  Rocío Barrios; Javier Montero; Miguel-Angel González-Moles; Pilar Baca; Manuel Bravo
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2013-07-01

5.  Variations in concerns reported on the patient concerns inventory in patients with head and neck cancer from different health settings across the world.

Authors:  Simon N Rogers; Alvaro Alvear; Alexandre Anesi; Emmanuel Babin; Ali Balik; Martin Batstone; Phillipp Brockmeyer; Claudia Celedon Carrasco; Chih-Yen Chien; Magdalena Chirila; Kanchan P Dholam; Jennifer G Doss; Caterina Finizia; Wan M Nabilah Ghani; Sandeep V Gurav; Kathreena Kadir; Mateusz Kolator; Roberto Lima; Yu-Tsai Lin; Simon Nhongo; Meltem Ozdemir-Karatas; Kadriye Peker; Zoran Pesic; Pierre Ransy; Izabella Santos; Henning Schliephake; Ketan Shah; Fernanda Souza; Geethu Sunil; Krishnakumar Thankappan; Ylva Tiblom Ehrsson; Cristina Tiple; Lisa Tuomi; Sara Valerini; Pablo Vasquez Lara; Tomasz Zatoński; Derek Lowe
Journal:  Head Neck       Date:  2019-12-13       Impact factor: 3.147

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.